Home

Th Möglich entscheiden anti met Nützlich Strafe zusammenzählen

Recombinant Anti-Met (c-Met) antibody [SP44] - C-terminal KO Tested (ab227637)
Recombinant Anti-Met (c-Met) antibody [SP44] - C-terminal KO Tested (ab227637)

Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer | SpringerLink
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer | SpringerLink

c-Met (Cytoplasmic) antibody (25869-1-AP) | Proteintech
c-Met (Cytoplasmic) antibody (25869-1-AP) | Proteintech

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect
Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer - ScienceDirect

c-Met Monoclonal Antibody (3D4) (18-7366)
c-Met Monoclonal Antibody (3D4) (18-7366)

Recombinant Anti-Met (c-Met) antibody [EP1454Y] - N-terminal KO Tested (ab51067)
Recombinant Anti-Met (c-Met) antibody [EP1454Y] - N-terminal KO Tested (ab51067)

HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram
HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram

Met Antibody | Cell Signaling Technology
Met Antibody | Cell Signaling Technology

Biomedicines | Free Full-Text | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
Biomedicines | Free Full-Text | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy

They Should Be in Jail': Nan Goldin, Anti-Sackler Opioid Activists Take Fight to Guggenheim, Met – ARTnews.com
They Should Be in Jail': Nan Goldin, Anti-Sackler Opioid Activists Take Fight to Guggenheim, Met – ARTnews.com

Met (c Met) Polyclonal Antibody – Bioss
Met (c Met) Polyclonal Antibody – Bioss

c-Met (Cytoplasmic) antibody (25869-1-AP) | Proteintech
c-Met (Cytoplasmic) antibody (25869-1-AP) | Proteintech

Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect

c-Met Polyclonal Antibody (PA5-85951)
c-Met Polyclonal Antibody (PA5-85951)

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy - Biocytogen
AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy - Biocytogen

Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition | Journal of Nuclear Medicine
Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition | Journal of Nuclear Medicine

Recombinant Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)
Recombinant Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | PNAS
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | PNAS

IJMS | Free Full-Text | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain
IJMS | Free Full-Text | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain

InlB-Dependent Internalization of Listeria Is Mediated by the Met Receptor Tyrosine Kinase: Cell
InlB-Dependent Internalization of Listeria Is Mediated by the Met Receptor Tyrosine Kinase: Cell

The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents - ScienceDirect
The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents - ScienceDirect

Frontiers | The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy
Frontiers | The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

Amivantamab (JNJ-61186372) is a Human EGFR-MET Bispecific Antibody - Network of Cancer Research
Amivantamab (JNJ-61186372) is a Human EGFR-MET Bispecific Antibody - Network of Cancer Research

Anti-c-Met antibody
Anti-c-Met antibody

Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering | Scientific Reports
Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering | Scientific Reports

Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY

MET is required for the recruitment of anti-tumoural neutrophils | Nature
MET is required for the recruitment of anti-tumoural neutrophils | Nature